A new plant for the biotechnological production of pharmaceuticals is being built in Ulm south of Germany. Pharmaceutical company Teva is investing 438 million euros in the site for this purpose

The “Genesis” project at the group’s German headquarters comprises an eight-story office wing and an adjoining six-story production area on a floor area of 4,700 square meters.

ITKP supports TEVA Automation in the commissioning and qualification of biotechnological analogues in the context of the construction of a new plant for the production of pharmaceuticals.

In the context of the implementation of the OSISoft PI Historian, ITKP takes over validation and qualification tasks together with TEVA.